DK1250328T3 - Dihydro-1,3,5-triazin-aminderivater og terapeutisk anvendelse deraf - Google Patents

Dihydro-1,3,5-triazin-aminderivater og terapeutisk anvendelse deraf

Info

Publication number: DK1250328T3
Authority: DK; Denmark
Prior art keywords: dihydro; therapeutic use; amine derivatives; triazine amine; triazine
Prior art date: 2000-01-26

Application number

DK01907700T

Other languages

English (en)

Other versions

DK1250328T4 (da

Inventor

Liliane Doare

Gerard Moinet

Daniel Cravo

Micheline Kergoat

Didier Mesangeau

Original Assignee

Merck Sante Sas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-26

Filing date

2001-01-25

Publication date

2006-10-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8846333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1250328(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-01-25 Application filed by Merck Sante Sas filed Critical Merck Sante Sas

2006-10-30 Application granted granted Critical

2006-10-30 Publication of DK1250328T3 publication Critical patent/DK1250328T3/da

2010-06-28 Publication of DK1250328T4 publication Critical patent/DK1250328T4/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/72—Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Hematology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK01907700.7T 2000-01-26 2001-01-25 Dihydro-1,3,5-triazindiaminderivater og terapeutisk anvendelse deraf DK1250328T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0000996A FR2804113B1 (fr)	2000-01-26	2000-01-26	Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
PCT/FR2001/000241 WO2001055122A1 (fr)	2000-01-26	2001-01-25	Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique

Publications (2)

Publication Number	Publication Date
DK1250328T3 true DK1250328T3 (da)	2006-10-30
DK1250328T4 DK1250328T4 (da)	2010-06-28

Family

ID=8846333

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01907700.7T DK1250328T4 (da)	2000-01-26	2001-01-25	Dihydro-1,3,5-triazindiaminderivater og terapeutisk anvendelse deraf

Country Status (37)

Country	Link
US (4)	US7034021B2 (da)
EP (1)	EP1250328B2 (da)
JP (1)	JP4926357B2 (da)
KR (1)	KR100722438B1 (da)
CN (1)	CN1195743C (da)
AP (1)	AP2002002578A0 (da)
AR (1)	AR027293A1 (da)
AT (1)	ATE332294T1 (da)
AU (1)	AU782307B2 (da)
BG (1)	BG106933A (da)
BR (1)	BRPI0107815B8 (da)
CA (1)	CA2397636C (da)
CY (1)	CY1105344T1 (da)
CZ (1)	CZ303445B6 (da)
DE (1)	DE60121294T3 (da)
DK (1)	DK1250328T4 (da)
EA (1)	EA005378B1 (da)
EE (1)	EE05003B1 (da)
ES (1)	ES2267715T5 (da)
FR (1)	FR2804113B1 (da)
HK (1)	HK1050529A1 (da)
HR (1)	HRP20020625A2 (da)
HU (1)	HU230790B1 (da)
IL (1)	IL150530A0 (da)
IS (1)	IS6467A (da)
MA (1)	MA25650A1 (da)
MX (1)	MXPA02007232A (da)
NO (1)	NO20023532L (da)
OA (1)	OA12165A (da)
PL (1)	PL205345B1 (da)
PT (1)	PT1250328E (da)
SI (1)	SI1250328T2 (da)
SK (1)	SK287647B6 (da)
TN (1)	TNSN01012A1 (da)
WO (1)	WO2001055122A1 (da)
YU (1)	YU55602A (da)
ZA (1)	ZA200205314B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2804113B1 (fr) *	2000-01-26	2004-06-18	Lipha	Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
MXPA05006450A (es) *	2002-12-17	2005-08-19	Hamari Chemicals Ltd	Nuevo derivado de 2,4-diamino-1,3,5-triazina.
FR2853650B1 (fr) *	2003-04-10	2006-07-07	Merck Sante Sas	Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
DE602006018456D1 (de) *	2005-06-14	2011-01-05	Schering Corp	Herstellung und verwendung von verbindungen als aspartylproteasehemmer
FR2896160B1 (fr) *	2006-01-13	2008-04-25	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896157B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896161B1 (fr) *	2006-01-13	2008-04-04	Merck Sante Soc Par Actions Si	Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896158B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) *	2006-01-13	2008-09-12	Merck Sante Soc Par Actions Si	Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
DE102007054416A1 (de)	2007-11-13	2009-05-14	Studiengesellschaft Kohle Mbh	Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) *	2008-02-02	2009-08-06	Merck Patent Gmbh	Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
MX2010012626A (es) *	2008-05-20	2011-02-22	Merck Sharp & Dohme	Produccion eficiente de proteinas heterologas utilizando inhibidores de manosil transferasa.
CA2725011A1 (en) *	2008-05-23	2009-11-26	Poxel Sas	Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
JPWO2010024225A1 (ja) *	2008-08-25	2012-01-26	浜理薬品工業株式会社	新規ジヒドロトリアジン誘導体
ES2573266T3 (es) *	2008-12-12	2016-06-06	Poxel	Compuestos de tetrahidrotriazina para tratar enfermedades relacionadas con la actividad de AMPK
ES2530223T3 (es) *	2008-12-12	2015-02-27	Poxel S.A.S.	Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
WO2010103040A1 (en)	2009-03-10	2010-09-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
WO2010109015A1 (en)	2009-03-26	2010-09-30	Poxel	Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (fr) *	2009-07-17	2011-01-21	Merck Sante Sas	Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) *	2009-07-17	2011-12-02	Merck Sante Sas	Derives amines de dihydro-1,3,5-triazine
FR2948028B1 (fr)	2009-07-17	2011-12-02	Merck Sante Sas	Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
ES2577930T3 (es) *	2010-06-09	2016-07-19	Poxel	Derivados de triazina para retrasar el inicio de la diabetes tipo 1
TWI436768B (zh) *	2010-06-09	2014-05-11	Poxel	第２型糖尿病之治療
EA022300B1 (ru)	2010-12-01	2015-12-30	Поксел	Разделение энантиомеров 2-амино-3,6-дигидро-4-диметиламино-6-метил-1,3,5-триазина с использованием винной кислоты
RU2658819C2 (ru) *	2016-05-26	2018-06-25	федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет"	Применение гетероциклических гидразонов в качестве средств, обладающих антигликирующей активностью
FR3068601B1 (fr)	2017-07-05	2021-02-19	Eric Joseph Marie Fulgence Janin	Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
BR112020006472A2 (pt)	2017-10-02	2020-10-06	Poxel	método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep)
MX2020013210A (es) *	2018-06-06	2021-02-26	Metavant Sciences Gmbh	Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica.
KR20210003786A (ko)	2018-06-14	2021-01-12	폭셀	당뇨병의 치료에서 사용하기 위한 트리아진 유도체를 포함하는 필름 코팅정
WO2022152138A1 (zh) *	2021-01-15	2022-07-21	中国医药研究开发中心有限公司	稠和杂环类化合物及其制备方法和医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3287366A (en) *	1963-12-24	1966-11-22	American Cyanamid Co	Novel 1, 2-dihydro-s-triazines
US3286366A (en) *	1964-10-26	1966-11-22	Seligman Monroe	Apparatus for freeze drying products in small containers
JPS4856692A (da) *	1971-11-19	1973-08-09
JPS4864088A (da) *	1971-12-13	1973-09-05
JPS5414986A (en) *	1977-07-01	1979-02-03	Taiho Pharmaceutical Co Ltd	Production of dihydrooss triazine derivative
US4246408A (en) *	1979-03-08	1981-01-20	Icn Pharmaceuticals	Imidazo[1,2-a]-s-triazine
GR74944B (da) *	1980-07-02	1984-07-12	Merck & Co Inc
US4277602A (en) *	1980-07-02	1981-07-07	Merck & Co., Inc.	3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4576945A (en) *	1982-10-26	1986-03-18	Sanders Mark E	Hexaalkylmelamine-amino-oxy compounds
JPS6141915A (ja)	1984-08-03	1986-02-28	Omron Tateisi Electronics Co	測距装置
DD257010A1 (de) *	1987-01-13	1988-06-01	Berlin Chemie Veb	Ergotrope mittel
DE3801113A1 (de) *	1987-07-23	1989-02-02	Bayer Ag	Substituierte triazine
IT1244870B (it) *	1990-09-11	1994-09-12	Ministero Dall Uni E Della Ric	Composti ammelinici
DE19641692A1 (de) *	1996-10-10	1998-04-23	Bayer Ag	Substituierte 2,4-Diamino-1,3,5-triazine
EP1037886B1 (en) *	1997-12-12	2003-05-02	Abbott Laboratories	Triazine angiogenesis inhibitors
FR2804113B1 (fr) *	2000-01-26	2004-06-18	Lipha	Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

2000
- 2000-01-26 FR FR0000996A patent/FR2804113B1/fr not_active Expired - Lifetime
2001
- 2001-01-24 TN TNTNSN01012A patent/TNSN01012A1/fr unknown
- 2001-01-25 AT AT01907700T patent/ATE332294T1/de active
- 2001-01-25 EP EP01907700A patent/EP1250328B2/fr not_active Expired - Lifetime
- 2001-01-25 SK SK976-2002A patent/SK287647B6/sk not_active IP Right Cessation
- 2001-01-25 DE DE60121294T patent/DE60121294T3/de not_active Expired - Lifetime
- 2001-01-25 SI SI200130600T patent/SI1250328T2/sl unknown
- 2001-01-25 OA OA1200200225A patent/OA12165A/fr unknown
- 2001-01-25 WO PCT/FR2001/000241 patent/WO2001055122A1/fr active IP Right Grant
- 2001-01-25 CN CNB018041027A patent/CN1195743C/zh not_active Expired - Lifetime
- 2001-01-25 MX MXPA02007232A patent/MXPA02007232A/es active IP Right Grant
- 2001-01-25 EA EA200200790A patent/EA005378B1/ru not_active IP Right Cessation
- 2001-01-25 AU AU35603/01A patent/AU782307B2/en not_active Expired
- 2001-01-25 BR BR0107815A patent/BRPI0107815B8/pt not_active IP Right Cessation
- 2001-01-25 US US10/181,223 patent/US7034021B2/en not_active Expired - Lifetime
- 2001-01-25 CA CA2397636A patent/CA2397636C/fr not_active Expired - Lifetime
- 2001-01-25 HU HU0204087A patent/HU230790B1/hu unknown
- 2001-01-25 PT PT01907700T patent/PT1250328E/pt unknown
- 2001-01-25 DK DK01907700.7T patent/DK1250328T4/da active
- 2001-01-25 KR KR1020027009459A patent/KR100722438B1/ko active IP Right Grant
- 2001-01-25 CZ CZ20022462A patent/CZ303445B6/cs not_active IP Right Cessation
- 2001-01-25 EE EEP200200414A patent/EE05003B1/xx unknown
- 2001-01-25 ES ES01907700T patent/ES2267715T5/es not_active Expired - Lifetime
- 2001-01-25 IL IL15053001A patent/IL150530A0/xx unknown
- 2001-01-25 YU YU55602A patent/YU55602A/sh unknown
- 2001-01-25 PL PL357191A patent/PL205345B1/pl unknown
- 2001-01-25 AP APAP/P/2002/002578A patent/AP2002002578A0/en unknown
- 2001-01-25 JP JP2001555064A patent/JP4926357B2/ja not_active Expired - Lifetime
- 2001-01-26 AR ARP010100337A patent/AR027293A1/es active IP Right Grant
2002
- 2002-07-03 ZA ZA2002/05314A patent/ZA200205314B/en unknown
- 2002-07-11 IS IS6467A patent/IS6467A/is unknown
- 2002-07-17 BG BG106933A patent/BG106933A/xx unknown
- 2002-07-22 MA MA26737A patent/MA25650A1/fr unknown
- 2002-07-24 HR HR20020625A patent/HRP20020625A2/hr not_active Application Discontinuation
- 2002-07-24 NO NO20023532A patent/NO20023532L/no not_active Application Discontinuation
2003
- 2003-04-11 HK HK03102653A patent/HK1050529A1/xx not_active IP Right Cessation
2005
- 2005-03-22 US US11/085,145 patent/US7452883B2/en not_active Expired - Lifetime
2006
- 2006-09-08 CY CY20061101287T patent/CY1105344T1/el unknown
2007
- 2007-10-30 US US11/976,936 patent/US7767676B2/en not_active Expired - Fee Related
- 2007-10-31 US US11/979,140 patent/US20080108591A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20020075395A (ko)	2002-10-04
US20080108591A1 (en)	2008-05-08
OA12165A (fr)	2006-05-08
CA2397636A1 (fr)	2001-08-02
SK287647B6 (sk)	2011-05-06
AP2002002578A0 (en)	2002-09-30
HK1050529A1 (en)	2003-06-27
CN1404472A (zh)	2003-03-19
PL205345B1 (pl)	2010-04-30
HU230790B1 (en)	2018-05-02
DK1250328T4 (da)	2010-06-28
AU782307B2 (en)	2005-07-21
DE60121294T3 (de)	2010-09-23
CZ20022462A3 (cs)	2003-04-16
EE05003B1 (et)	2008-04-15
CY1105344T1 (el)	2010-03-03
ZA200205314B (en)	2005-07-27
SK9762002A3 (en)	2003-05-02
HUP0204087A3 (en)	2006-01-30
JP2003520858A (ja)	2003-07-08
EA005378B1 (ru)	2005-02-24
DE60121294T2 (de)	2007-08-30
CA2397636C (fr)	2010-04-06
FR2804113B1 (fr)	2004-06-18
EP1250328B1 (fr)	2006-07-05
HRP20020625A2 (en)	2003-10-31
PL357191A1 (en)	2004-07-26
BRPI0107815B1 (pt)	2017-08-29
US20050165022A1 (en)	2005-07-28
IS6467A (is)	2002-07-11
US7452883B2 (en)	2008-11-18
BRPI0107815B8 (pt)	2021-05-25
CZ303445B6 (cs)	2012-09-19
ATE332294T1 (de)	2006-07-15
FR2804113A1 (fr)	2001-07-27
EP1250328A1 (fr)	2002-10-23
NO20023532D0 (no)	2002-07-24
IL150530A0 (en)	2003-02-12
JP4926357B2 (ja)	2012-05-09
ES2267715T5 (es)	2010-06-10
CN1195743C (zh)	2005-04-06
BG106933A (en)	2003-07-31
AU3560301A (en)	2001-08-07
NO20023532L (no)	2002-09-25
US20030109530A1 (en)	2003-06-12
EE200200414A (et)	2003-10-15
PT1250328E (pt)	2006-10-31
SI1250328T2 (sl)	2010-09-30
EA200200790A1 (ru)	2003-02-27
US7767676B2 (en)	2010-08-03
WO2001055122A1 (fr)	2001-08-02
US20080108619A1 (en)	2008-05-08
MXPA02007232A (es)	2003-10-15
EP1250328B2 (fr)	2010-04-21
SI1250328T1 (sl)	2006-10-31
YU55602A (sh)	2005-03-15
US7034021B2 (en)	2006-04-25
MA25650A1 (fr)	2002-12-31
HUP0204087A2 (hu)	2003-04-28
KR100722438B1 (ko)	2007-05-29
AR027293A1 (es)	2003-03-19
DE60121294D1 (de)	2006-08-17
BR0107815A (pt)	2002-10-29
ES2267715T3 (es)	2007-03-16
TNSN01012A1 (fr)	2005-11-10

Publication	Publication Date	Title
DK1250328T3 (da)	2006-10-30	Dihydro-1,3,5-triazin-aminderivater og terapeutisk anvendelse deraf
NO20012567D0 (no)	2001-05-25	Azepinoindolderivater, fremstilling og anvendelse derav
NO20021379D0 (no)	2002-03-20	Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20021449D0 (no)	2002-03-22	Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
MXPA03006260A (es)	2003-09-22	Derivados de amina sustituidos y metodos de uso.
IS6385A (is)	2002-05-15	Ný notkun og nýjar N-asabísýkló-amíð afleiður
IS5696A (is)	2000-10-31	Mótefni gegn CD23, afleiður þeirra og meðferðarnotkun þeirra
NO20024742L (no)	2002-11-25	Heterocykliske forbindelser, deres fremstilling og anvendelse
IS6661A (is)	2002-12-19	Bensimídasólafleiður, framleiðsla þeirra og meðferðarleg notkun
NO20042635L (no)	2004-06-23	5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin
NO20014270L (no)	2001-11-05	Pyridopyranoazepinderivater, deres fremstilling og terapeutisk anvendelse
NO20031838D0 (no)	2003-04-24	Benzokazinonderivater, deres fremstilling og anvendelse
IS6420A (is)	2002-06-13	Setnar Fenýl-píperazín afleiður, framleiðsla þeirra og notkun
DK1417189T3 (da)	2006-05-08	Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
DK1043307T3 (da)	2003-09-22	3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
NO986174D0 (no)	1998-12-29	Triazinderivater og anvendelse derav
NO20014050D0 (no)	2001-08-20	1-aryl-1,3,5-triazin-4-tion-2,6-dioner, fremstilling derav og anvendelse derav som herbicider
ZA200309513B (en)	2004-12-08	Novel heterocyclic derivatives and medicinal use thereof.
NO20024107L (no)	2002-09-27	Tienopyridin derivater, deres fremstilling og anvendelse
NO20001782D0 (no)	2000-04-06	3-amino-3-arylpropan-1-ol-derivater, deres fremstilling og anvendelse
DK1235809T3 (da)	2004-03-15	Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler
NO20022482L (no)	2002-07-24	2-arylkinolinderivater, fremgangsmåte og terapeutisk anvendelse derav
DK1177196T3 (da)	2004-06-21	Heteroaryldiazabicycloalkaner, deres fremstilling og anvendelse
DK1309594T3 (da)	2005-04-25	Benzimidazolderivater, fremstilling heraf og terapeutisk anvendelse heraf
ZA200305198B (en)	2004-06-30	Substituted amine derivatives and methods of use.